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Placental ischemia 
and preeclampsia
Recent, exciting discoveries have 
made inroads into the pathogenesis of 
preeclampsia, a syndrome characterized 
by hypertension, proteinuria, and 
changes in the glomerular endothelium. 
Chief among these is the fi nding 
by Karumanchi and colleagues that 
patients with preeclampsia have high 
circulating levels of soluble fms-like 
tyrosine kinase 1 (sFLT-1), which 
prevents its normal function. 
(sFLT-1 is a protein that binds to 
vascular endothelial growth factor.)  As 
they report in this issue, Makris et al. 
tested another hypothesis: that placental 
ischemia is critical for the development 
of preeclampsia. Using pregnant 
baboons, they induced placental 
ischemia by ligating the uterine artery. 
Th is resulted in a syndrome similar to 
human preeclampsia in that the animals 
developed hypertension, proteinuria, 
and glomerular endothelial anomalies. 
Remarkably, they also had elevated 
plasma levels of sFLT-1 and increased 
RNA expression of the protein in the 
placenta. Th ese results demonstrate 
a pathogenic link between ischemia 
and sFLT-1 overexpression. See page 
977. An excellent Commentary by 
Karumanchi on these results can be 
found on page 959.
Turnover of 
lipoprotein(a) in 
kidney disease
One of the most atherogenic proteins 
in plasma is lipoprotein(a), a low-
density lipoprotein particle that is 
covalently attached to a glycoprotein 
called apolipoprotein(a). Like many 
lipoproteins, apolipoprotein(a) is 
synthesized and secreted by the liver into 
the plasma, where it circulates. Because 
atherosclerosis seems to be accelerated 
in end-stage renal disease (ESRD), it 
is critical to test whether the kidney 
is involved in the disposal of plasma 
proteins. Dieplinger and colleagues 
studied the half-life of apolipoprotein(a) 
in healthy patients and patients with 
ESRD. Th ey found that patients with 
ESRD had a higher plasma level of 
apolipoprotein(a), suggesting that, 
indeed, the kidney may be involved 
in its catabolism. Th ey also measured 
the rate of synthesis and found it to be 
similar in patients and controls, further 
documenting this idea. Finally, the 
fractional catabolic rate in patients with 
ESRD was found to be almost half of 
that in controls. Th ese studies show that 
the kidney plays a signifi cant role in the 
disposal of lipoproteins, a fi nding that 
begins to provide an explanation for the 
enhanced atherogenesis in renal disease. 
See page 1036.
Dendritic cells in 
human glomerular 
diseases
An exciting new development in 
nephrology has been the recent 
discovery that the kidney contains 
resident dendritic cells. When 
Woltman et al. studied these cells in 
human kidney biopsies, they found 
that at least two subsets of these cells 
were present in the interstitium of 
the kidney cortex. Th ese cells include 
dendritic cells from the myeloid lineage 
and others from the plasmacytoid 
lineages. Further, these subsets 
seemed to vary in diff erent types of 
renal diseases. Th is research begins an 
investigation into the exciting frontier 
in cellular immunology about the role 
of dendritic cells in the initiation of 
immune response. See page 1001.
